Kymera Therapeutics
KYMR106.6403.10% ( -3.410 )
Kymera Therapeutics (KYMR)
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrad...
- Open
- 108.775
- High
- 110.360
- Low
- 105.505
- Prev. Close
- 110.050
- Volume
- 302.17K
- Turnover
- 32.40M
- Avg Price
- 107.229
- Bid/Ask Ratio
- --
- Amplitude
- 4.41%
- 52wk High
- 130.050
- Volume Ratio
- 1.10
- Turnover Ratio
- 0.56%
Kymera Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$127.5219.19%
Forecast & RatingStrong buy
23analysts
- Strong buy73.91%
- Buy17.39%
- Hold8.70%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 18 hours ago
Kymera Therapeutics files initial beneficial ownership statement for Chief Medical Officer Terence Rooney
- PUBT · 20 hours ago
Kymera Therapeutics names Terence Rooney chief medical officer as Jared Gollob retires
- PR Newswire · 1 day ago, 07:49 AM
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
- Global Report · Jul 24 at 04:13 AM
Capital Reallocation on Wall Street’s Fringes: AI Spillovers and Cross-Border Headwinds
- prnewswire · Jul 16 at 10:13 AM
11:13 ETSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
- Simplywall · Jul 10 at 12:02 PM
Does Leadership Hire And Benchmark Additions Change The Bull Case For Kymera Therapeutics (KYMR)?
